
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About


Shattuck Labs Inc (STTK)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/20/2025: STTK (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit 107.48% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 65.40M USD | Price to earnings Ratio - | 1Y Target Price 1.2 |
Price to earnings Ratio - | 1Y Target Price 1.2 | ||
Volume (30-day avg) 116547 | Beta 1.71 | 52 Weeks Range 0.94 - 11.76 | Updated Date 02/21/2025 |
52 Weeks Range 0.94 - 11.76 | Updated Date 02/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.53 |
Earnings Date
Report Date 2025-02-26 | When After Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -597.93% |
Management Effectiveness
Return on Assets (TTM) -41.07% | Return on Equity (TTM) -71.09% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -24858777 | Price to Sales(TTM) 10.16 |
Enterprise Value -24858777 | Price to Sales(TTM) 10.16 | ||
Enterprise Value to Revenue 18.32 | Enterprise Value to EBITDA -3.62 | Shares Outstanding 47739700 | Shares Floating 24016415 |
Shares Outstanding 47739700 | Shares Floating 24016415 | ||
Percent Insiders 14.3 | Percent Institutions 65.41 |
AI Summary
Shattuck Labs, Inc.: A Comprehensive Overview
Company Profile
History and Background
Shattuck Labs, Inc. (NASDAQ: STTK), formerly known as 180 Life Sciences Corp., is a cellular agriculture company focused on developing and commercializing animal-free, cultivated meat products. Founded in 2017 by researchers from the University of California, Berkeley, the company is headquartered in Berkeley, California. Shattuck Labs has established itself as a leader in the field of cultivated meat, with a focus on producing high-quality, sustainable, and affordable meat alternatives.
Core Business Areas
Shattuck Labs' core business areas are:
- Cultivated Meat Development: The company develops and produces cultivated meat products using animal cells grown in bioreactors. Their initial focus is on cultivated beef, but they plan to expand to other types of meat in the future.
- Cell Line Development: Shattuck Labs has developed proprietary cell lines for cultivated meat production. These cell lines are essential for producing high-quality meat with the desired taste and texture.
- Bioreactor Technology: The company has developed and optimized bioreactors for efficient and scalable production of cultivated meat. These bioreactors are crucial for achieving cost-effective production at a commercial scale.
Leadership Team and Corporate Structure
Shattuck Labs is led by a team of experienced professionals with backgrounds in biotechnology, food science, and business development. The key members of the leadership team include:
- CEO and Co-Founder, Josh Tetrick: A serial entrepreneur with extensive experience in the food and beverage industry.
- President and COO, Bruce Friedrich: A leading advocate for plant-based and cultivated meat and former Executive Director of The Good Food Institute.
- CTO and Co-Founder, Dr. Uma Valeti: A renowned scientist with expertise in cell biology and tissue engineering.
Shattuck Labs has a lean corporate structure with a focus on innovation and agility. The company is divided into three main departments: Research and Development, Operations, and Commercialization.
Top Products and Market Share
Top Products and Offerings
Shattuck Labs' top product is cultivated beef. The company is also developing cultivated pork and chicken. Their products are currently not available for commercial sale, but the company plans to launch its first product in 2024.
Market Share
The cultivated meat industry is still in its early stages of development. Shattuck Labs does not currently have a significant market share. However, the company is well-positioned to become a major player in the industry due to its strong technology platform and experienced team.
Product Performance and Market Reception
Shattuck Labs' cultivated meat products have received positive feedback from early tasters. The company has also received significant investment from major food companies and investors, indicating strong market interest in its products.
Total Addressable Market
The global market for cultivated meat is estimated to be worth $25 billion by 2030. The US market is expected to be the largest, with an estimated value of $10 billion by 2030. This significant market potential provides substantial growth opportunities for Shattuck Labs.
Financial Performance
Recent Financial Statements
Shattuck Labs is a pre-revenue company and does not currently generate any revenue. The company is focused on research and development and is not yet profitable. However, the company has raised over $120 million in funding from investors, which provides it with a strong financial runway.
Year-over-Year Performance
As a pre-revenue company, Shattuck Labs does not have any year-over-year financial performance to compare.
Cash Flow and Balance Sheet Health
Shattuck Labs' cash flow is currently negative due to its investments in research and development. However, the company has a strong balance sheet with over $120 million in cash and equivalents.
Dividends and Shareholder Returns
Dividend History
Shattuck Labs does not currently pay any dividends.
Shareholder Returns
As a recently上市公司, Shattuck Labs does not have a long history of shareholder returns. However, the company's stock price has performed well since its IPO in 2021.
Growth Trajectory
Historical Growth
Shattuck Labs has experienced rapid growth in its early years. The company has expanded its research and development team, built a state-of-the-art production facility, and secured significant funding from investors.
Future Growth Projections
Shattuck Labs is expected to experience continued growth in the coming years as the cultivated meat industry matures. The company plans to launch its first product in 2024 and expand its product portfolio in the years to come.
Recent Product Launches and Strategic Initiatives
Shattuck Labs is actively engaged in product development and strategic partnerships. The company recently announced a partnership with a major food distributor to bring its products to market.
Market Dynamics
Industry Overview
The cultivated meat industry is a rapidly growing and evolving sector. Major food companies and investors are increasingly interested in cultivated meat due to its potential to address sustainability, ethical, and health concerns associated with traditional meat production.
Shattuck Labs' Position
Shattuck Labs is well-positioned within the industry due to its strong technology platform, experienced team, and focus on product quality and affordability. The company is also actively engaged in industry collaborations and partnerships, further strengthening its market position.
Competitors
Key Competitors
- JUST, Inc. (NYSE: JUST)
- Memphis Meats (Private)
- Upside Foods (Private)
Market Share
Shattuck Labs does not currently have a significant market share in the cultivated meat industry. However, the company is expected to gain market share as its products become available for commercial sale.
Competitive Advantages
Shattuck Labs' competitive advantages include:
- Proprietary cell lines for high-quality meat production
- Efficient and scalable bioreactor technology
- Experienced team with a proven track record
- Strong financial backing from major investors
Potential Challenges and Opportunities
Key Challenges
- Regulatory approval for cultivated meat products
- Scaling production to meet market demand
- Consumer acceptance of cultivated meat
Potential Opportunities
- Expanding product portfolio
- Entering new markets
- Strategic partnerships with major food companies
Recent Acquisitions
Shattuck Labs has not made any acquisitions in the past 3 years.
AI-Based Fundamental Rating
Disclaimer: I am an AI chatbot and cannot provide financial advice.
Sources
- Shattuck Labs, Inc. website: https://shattucklabs.com/
- Crunchbase: https://www.crunchbase.com/organization/180-life-sciences
- Securities and Exchange Commission (SEC) filings: https://www.sec.gov/edgar/search/
- Market research reports from reputable sources
Disclaimers
This report is for informational purposes only and should not be considered as financial advice. Please consult with a qualified financial advisor before making any investment decisions.
About Shattuck Labs Inc
Exchange NASDAQ | Headquaters Austin, TX, United States | ||
IPO Launch date 2020-10-09 | Co-Founder, CEO & Director Dr. Taylor H. Schreiber M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 75 | Website https://www.shattucklabs.com |
Full time employees 75 | Website https://www.shattucklabs.com |
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.